Yes, lisinopril can cause swelling, and the mechanism is a bradykinin buildup rather than an allergy. The signature pattern is angioedema: deep swelling of the lips, tongue, face, or throat that develops in roughly 0.1% to 0.7% of patients taking ACE inhibitors, usually within the first weeks to months of therapy. It can also cause dependent leg swelling through a separate, simpler route—blood pressure lowering and fluid shifts. The throat form is the one that kills, which is why any airway involvement is a stop-the-drug, call-for-help event, not a wait-and-see symptom.
The mechanism: why lisinopril swells tissue
Lisinopril blocks the angiotensin-converting enzyme. That enzyme does two jobs at once: it converts angiotensin I into angiotensin II, and it degrades bradykinin into inactive fragments. Blocking the enzyme lowers blood pressure—and simultaneously lets bradykinin accumulate.
Bradykinin is a potent vasodilator. It makes capillaries leak plasma proteins into surrounding tissue, which draws water with them. In most people this produces nothing noticeable. In susceptible people, the leak concentrates in the loose connective tissue of the lips, tongue, periorbital area, and larynx—areas with abundant submucosal space and little resistance to fluid.
This is the key distinction from an allergic reaction. Histamine-driven angioedema responds to epinephrine and antihistamines because it is mast-cell mediated. Bradykinin-driven angioedema does not. In plain terms: the standard allergy toolkit is largely the wrong toolkit for this problem, and that single fact explains most of the treatment failures in the literature.
A second, separate pathway explains ordinary leg swelling. ACE inhibitors reduce angiotensin II, which lowers aldosterone and mildly reduces sodium retention. Combined with arteriolar dilation and gravity, this can produce mild dependent edema in perhaps 1% to 3% of users—far more common, far less dangerous, and mechanistically unrelated to bradykinin.
How often does it happen, and who is at risk
Pooled trial and observational data put ACE-inhibitor angioedema at roughly 0.1% to 0.7% of treated patients, with black patients at approximately 3 to 4 times the risk of white patients—a range of about 0.3% to 1.5% in that group. The risk is highest in the first 30 days but never reaches zero; cases have been documented after years of stable use.
| Risk factor | Approximate effect on angioedema risk |
|---|---|
| Black ancestry | 3 to 4 times baseline |
| Prior ACE-inhibitor angioedema | 5 to 10 times baseline; recurrence without the drug class is common |
| Age over 65 | Roughly 1.5 to 2 times baseline |
| Female sex | Modest increase, about 1.5 times |
| Smoking | Associated with higher risk in several cohorts |
| Concurrent mTOR inhibitor (e.g., sirolimus) | Markedly elevated; case series flag this combination |
| History of angioedema of any cause | Higher baseline susceptibility |
The absolute numbers stay small. Even at 0.7%, that is roughly 7 cases per 1,000 treated patients—but with tens of millions of ACE-inhibitor prescriptions annually in the United States, the absolute case count is substantial, and the mortality from laryngeal involvement is estimated at up to 10% when the airway is not secured.
Timing: when swelling actually appears
The timing profile is the most useful triage tool a clinician has, because early swelling and late swelling mean different things.
| Time since starting lisinopril | Typical presentation | Interpretation |
|---|---|---|
| Day 1 to 7 | Lip or facial swelling, sometimes with rash | Early angioedema; highest vigilance |
| Week 2 to 4 | Tongue or periorbital swelling | Classic bradykinin window |
| Month 2 to 6 | Recurrent mild facial swelling | Often missed; drug should still be stopped |
| Month 6 to 24 | Isolated lip or tongue episodes | Late-onset angioedema, well documented |
| Year 2 and beyond | Any new angioedema without another cause | Still attributable; never assume "too late" |
| Any time | Laryngeal swelling with voice change or stridor | Emergency regardless of timing |
| Any time | Bilateral ankle swelling, no face or throat involvement | Usually hemodynamic, not bradykinin |
The clinical trap is the late case. A patient on lisinopril for three years who presents with tongue swelling is frequently worked up for food allergy, dental infection, or idiopathic angioedema before anyone considers the ACE inhibitor. The 2017 ACC/AHA hypertension guideline and subsequent allergy society position statements both note that angioedema can occur at any point during therapy, which is why the drug history must be taken in every case of unexplained orofacial swelling.
Swelling in the legs versus swelling in the throat
These are two different diseases wearing the same symptom word, and conflating them causes both undertreatment of the dangerous one and unnecessary panic about the benign one.
| Feature | Leg (dependent) edema | Angioedema (face, tongue, airway) |
|---|---|---|
| Mechanism | Vasodilation, reduced aldosterone, gravity | Bradykinin accumulation, capillary leak |
| Typical frequency | 1% to 3% | 0.1% to 0.7% |
| Onset | Weeks, gradual | Minutes to hours per episode |
| Symmetry | Usually both ankles | Usually asymmetric or focal |
| Skin appearance | Smooth, pitting, non-tender | Tight, non-pitting, often no itch or hives |
| Itching or hives | Absent | Absent in bradykinin type |
| Airway risk | None | High if tongue or larynx involved |
| Response to antihistamines | Not applicable | Poor |
| Response to epinephrine | Not applicable | Incomplete; not a substitute for airway management |
| Action | Review dose, salt, other drugs | Stop lisinopril, urgent assessment |
A useful rule of thumb: swelling that pits under a fingertip and improves overnight with leg elevation is almost never angioedema. Swelling that feels firm, appears suddenly, and involves the mouth or throat is almost never simple edema.
The non-obvious part: rechallenge and cross-reactivity
The most commonly repeated error is the assumption that switching from lisinopril to another ACE inhibitor is safe. It is not. Angioedema is a class effect, and the estimated cross-reactivity rate on rechallenge with a different ACE inhibitor runs roughly 20% to 40% in published series—meaning one in three to one in five patients who react once will react again if given another drug in the same class.
A second correction concerns ARBs. The older teaching was that angiotensin receptor blockers were completely safe after ACE-inhibitor angioedema. The current picture is more nuanced: ARB cross-reactivity is low, generally estimated under 10%, but not zero, and the 2022 consensus from allergy and immunology societies recommends a supervised observation period of at least 2 to 4 hours after the first ARB dose in patients with prior ACE-inhibitor angioedema, with some experts extending to 6 hours. This is a meaningful change from blanket reassurance.
A third edge case: the swelling sometimes does not resolve quickly. Because bradykinin has to be metabolized through alternative pathways, episodes can persist 24 to 72 hours after the drug is stopped. A patient whose tongue swelling is unchanged 6 hours after the last pill has not necessarily failed treatment—the drug's effect on the enzyme persists longer than the drug's measurable plasma half-life of about 12 hours.
Distinguishing lisinopril swelling from other causes
Several conditions mimic ACE-inhibitor angioedema and each has a different fix.
- Hereditary angioedema: recurrent episodes since childhood, family history, no response to antihistamines; requires C1-esterase inhibitor testing.
- Allergic angioedema: usually with urticaria and itching, responds to antihistamines and epinephrine.
- Dental abscess or cellulitis: unilateral, tender, warm, with fever; needs antibiotics or drainage.
- Hypothyroidism: periorbital and facial puffiness with fatigue and weight gain; check TSH.
- Drug-induced edema from calcium channel blockers or NSAIDs: bilateral ankle swelling; review the full medication list.
- Idiopathic angioedema: diagnosis of exclusion; often responsive to antihistamines at higher doses.
In cases where the diagnosis is unclear, a trial off lisinopril for 4 to 8 weeks with substitution of an alternative antihypertensive is both diagnostic and therapeutic. If the swelling stops, the drug was the cause.
What to actually do
If you are on lisinopril and notice swelling, the response depends entirely on location and speed.
- Swelling of the tongue, throat, or back of the mouth, difficulty swallowing, voice change, or noisy breathing: call emergency services immediately. Do not drive yourself.
- Swelling of the lips or face without airway symptoms: stop lisinopril and contact your prescriber the same day.
- Mild bilateral ankle swelling with no facial involvement: mention it at your next visit; do not stop the drug on your own without advice.
- Keep the pill bottle available for the emergency team; the drug name and dose matter for treatment decisions.
- Document the date, time, and location of the swelling; this record determines future prescribing.
- Ask for an allergy or adverse-reaction notation in your medical record so the drug is not restarted in a future hospital visit.
After a confirmed episode, the standard is permanent discontinuation of all ACE inhibitors. Alternative antihypertensives include thiazide diuretics, calcium channel blockers, and—for many patients—ARBs under observation. The choice depends on kidney function, diabetes status, and heart failure history, which is why the substitution should be made by the prescriber and not inferred from a general list.
Limitations of the evidence
The frequency figures are the weakest part of this topic. Because angioedema is a clinical diagnosis with no confirmatory blood test, mild cases are underreported and severe cases are overrepresented in published series. The widely quoted 0.1% to 0.7% range comes largely from trial populations that excluded high-risk patients, so real-world rates in Black patients and in smokers are probably at or above the upper bound.
The cross-reactivity estimates for ARBs rest on smaller cohorts and carry wide confidence intervals. The recommendation for 2 to 4 hours of observation is expert consensus, not a randomized-trial finding. And the mechanism is well established for bradykinin—but why only some patients accumulate enough to swell remains incompletely understood, with genetic variation in the aminopeptidase P and dipeptidyl peptidase-4 pathways among the leading hypotheses rather than settled fact. Patients should be told what is well known: the risk is real, it is higher in certain groups, it can appear years into treatment, and the airway form requires immediate action.